The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
Open accessAbstract
A checkpoint operating in the G(2) phase of the cell cycle prevents entry into mitosis in the presence of DNA damage. UCN-01, a protein kinase inhibitor currently undergoing clinical trials for cancer treatment, abrogates G(2) checkpoint function and sensitizes p53-defective cancer cells to DNA-damaging agents. In most species, the G(2) checkpoint prevents the Cdc25 phosphatase from removing inhibitory phosphate groups from the mitosis-promoting kinase Cdc2. This is accomplished by maintaining Cdc25 in a phosphorylated form that binds 14-3-3 proteins. The checkpoint kinases, Chk1 and Cds1, are proposed to regulate the interactions between human Cdc25C and 14-3-3 proteins by phosphorylating Cdc25C on serine 216. 14-3-3 proteins, in turn, function to keep Cdc25C out of the nucleus. Here we report that UCN-01 caused loss of both serine 216 phosphorylation and 14-3-3 binding to Cdc25C in DNA-damaged cells. In addition, UCN-01 potently inhibited the ability of Chk1 to phosphorylate Cdc25C in vitro. In contrast, Cds1 was refractory to inhibition by UCN-01 in vitro, and Cds1 was still phosphorylated in irradiated cells treated with UCN-01. Thus, neither Cds1 nor kinases upstream of Cds1, such as ataxia telangiectasia-mutated, are targets of UCN-01 action in vivo. Taken together our results identify the Chk1 kinase and the Cdc25C pathway as potential targets of G(2) checkpoint abrogation by UCN-01.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
Self-citationLinkage of ATM to Cell Cycle Regulation by the Chk2 Protein Kinase
Matsuoka, S. (1998) · Science · doi:10.1126/science.282.5395.1893 · Cited by 1,322
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
Self-citationTyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis
Gould, K. L., & Nurse, P. (1989) · Nature · doi:10.1038/342039a0 · Cited by 1,218
cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2
Gautier, J., Solomon, M. J., Booher, R. N., Bazan, J. F., & Kirschner, M. W. (1991) · Cell · doi:10.1016/0092-8674(91)90583-k · Cited by 841
Draetta, G., & Beach, D. (1988) · Cell · doi:10.1016/0092-8674(88)90175-4 · Cited by 775
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Self-citation
Cited by
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
Role of cell cycle in mediating sensitivity to radiotherapy
Pawlik, T. M., & Keyomarsi, K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.03.005 · Cited by 1,102
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091
“This substrate has previously been used to monitor the activity of Chk1 (25, 56).”
BackgroundMethodInfluentialSelf-citationActivation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
PDK1, the master regulator of AGC kinase signal transduction
Mora, A., Komander, D., van Aalten, D. M. F., & Alessi, D. R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.022 · Cited by 810
Cellular Responses to DNA Damage
Norbury, C. J., & Hickson, I. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.367 · Cited by 623
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K. K., Zhou, B.-B., Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00048-5 · Cited by 559
Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase
Bulavin, D. V., Higashimoto, Y., Popoff, I. J., Gaarde, W. A., Basrur, V., Potapova, O., Appella, E., & Fornace, A. J. (2001) · Nature · doi:10.1038/35075107 · Cited by 532
Chemotherapeutic Approaches for Targeting Cell Death Pathways
Ricci, M. S., & Zong, W.-X. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-342 · Cited by 515
DNA damage checkpoint control in cells exposed to ionizing radiation
Iliakis, G., Wang, Y., Guan, J., & Wang, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206682 · Cited by 476
New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation
Chen, F., Castranova, V., & Shi, X. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61708-7 · Cited by 473
Pathways governing G1/S transition and their response to DNA damage
Bartek, J., & Lukas, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02114-7 · Cited by 471
Zhao, H., Watkins, J. L., & Piwnica-Worms, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182557299 · Cited by 461
Self-citationATM Mutations in Cancer: Therapeutic Implications
Choi, M., Kipps, T., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 453
Luker, K. E., Smith, M. C. P., Luker, G. D., Gammon, S. T., Piwnica-Worms, H., & Piwnica-Worms, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404041101 · Cited by 439
Self-citationHermeking, H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1230 · Cited by 437
DNA damage checkpoints in mammals
Niida, H., & Nakanishi, M. (2006) · Mutagenesis · doi:10.1093/mutage/gei063 · Cited by 432
Homologous recombinational repair of DNA ensures mammalian chromosome stability
Thompson, L. H., & Schild, D. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00115-4 · Cited by 429
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
14-3-3 proteins: regulation of subcellular localization by molecular interference
MUSLIN, A. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00131-5 · Cited by 417
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
Chk2 kinase — a busy messenger
Bartek, J., Falck, J., & Lukas, J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35103059 · Cited by 403
Control of mitosis by changes in the subcellular location of cyclin-B1–Cdk1 and Cdc25C
Takizawa, C. G., & Morgan, D. O. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00149-6 · Cited by 392
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening
Foloppe, N., Fisher, L. M., Howes, R., Potter, A., Robertson, A. G. S., & Surgenor, A. E. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.03.021 · Cited by 363
Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe
Castedo, M., Perfettini, J.-L., Roumier, T., & Kroemer, G. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401130 · Cited by 345
Cell-cycle dysregulation and anticancer therapy
Stewart, Z. A., Westfall, M. D., & Pietenpol, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00026-9 · Cited by 344
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Activation of mammalian Chk1 during DNA replication arrest
Feijoo, C., Hall-Jackson, C., Wu, R., Jenkins, D., Leitch, J., Gilbert, D. M., & Smythe, C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104099 · Cited by 318
Repair of and checkpoint response to topoisomerase I-mediated DNA damage
Pommier, Y., Redon, C., Rao, V. A., Seiler, J. A., Sordet, O., Takemura, H., Antony, S., Meng, L., Liao, Z., Kohlhagen, G., et al. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.016 · Cited by 302
Gatei, M., Sloper, K., Sörensen, C., Syljuäsen, R., Falck, J., Hobson, K., Savage, K., Lukas, J., Zhou, B.-B., Bartek, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210862200 · Cited by 300
Apoptosis and cancer chemotherapy
Makin, G., & Dive, C. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02124-9 · Cited by 297
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Self-citationGörgün, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., et al. (2010) · Blood · doi:10.1182/blood-2009-12-259523 · Cited by 274
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, C. X., Janetka, J. W., & Piwnica-Worms, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.009 · Cited by 271
Self-citationHeffernan, T. P., Simpson, D. A., Frank, A. R., Heinloth, A. N., Paules, R. S., Cordeiro-Stone, M., & Kaufmann, W. K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8552-8561.2002 · Cited by 251
Stojic, L., Mojas, N., Cejka, P., di Pietro, M., Ferrari, S., Marra, G., & Jiricny, J. (2004) · Genes & Development · doi:10.1101/gad.294404 · Cited by 246
Seiler, J. A., Conti, C., Syed, A., Aladjem, M. I., & Pommier, Y. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02278-06 · Cited by 226
S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function
Cliby, W. A., Lewis, K. A., Lilly, K. K., & Kaufmann, S. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106287200 · Cited by 205
Alkylating agents and cancer therapy
Ralhan, R., & Kaur, J. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.9.1061 · Cited by 147
Syljuåsen, R. G., Sørensen, C. S., Nylandsted, J., Lukas, C., Lukas, J., & Bartek, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2434 · Cited by 99
Cell-cycle responses to DNA damage in G2
Cuddihy, A. R., & O'Connell, M. J. (2003) · International Review of Cytology · doi:10.1016/s0074-7696(02)22013-6 · Cited by 89
Lossaint, G., Besnard, E., Fisher, D., Piette, J., & Dulić, V (2011) · Oncogene · doi:10.1038/onc.2011.135 · Cited by 83
“Moreover, UCN-01, a potent Chk1 inhibitor (Graves et al., 2000), abrogated G2 arrest only if p21 was depleted (Figure 2e and Supplementary Figure S4B) or absent, as in NHF-E6 (Supplementary Figure S5B).”
The G2 DNA Damage Checkpoint Delays Expression of Genes Encoding Mitotic Regulators
Crawford, D. F., & Piwnica-Worms, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103414200 · Cited by 79
Self-citationEquivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target
Liu, Y., & Kwiatkowski, D. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0622-t · Cited by 35
“When the S and G2/M checkpoints are abrogated by inhibition of Chk1, p53deficient cancer cells undergo mitotic catastrophe and apoptosis (9-14).”
Metadata
- Authors
- Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-02
- Volume
- 275
- Issue
- 8
- Pages
- 5600-5605
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105768236
- Cited by
- 544
- References
- 63
- FWCI
- 18.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.